



## **Regeneron Announces Presentation at the Cowen and Company 29th Annual Healthcare Conference**

March 12, 2009

Regeneron Announces Presentation at the Cowen and Company 29th Annual Healthcare Conference TARRYTOWN, N.Y.-- (BUSINESS WIRE)--Mar. 12, 2009-- Regeneron Pharmaceuticals, Inc. (Nasdaq: **REGN**) will webcast its presentation at the Cowen and Company 29<sup>th</sup> Annual Healthcare Conference on Monday, March 16, 2009. The presentation, which is scheduled for 4:40 p.m. Eastern Time, will provide an overview of the Company, including its three Phase 3 clinical programs. The session may be accessed through the Company's web site, [www.regeneron.com](http://www.regeneron.com), on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through April 15, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

Source: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Investor Relations:

Peter Dworkin, 914-345-7640

[peter.dworkin@regeneron.com](mailto:peter.dworkin@regeneron.com)

or

Media Relations:

Laura Lindsay, 914-345-7800

[laura.lindsay@regeneron.com](mailto:laura.lindsay@regeneron.com)

or

Kelly Hershkowitz, 212-845-5624

[khershkowitz@biosector2.com](mailto:khershkowitz@biosector2.com)